Previous 10 | Next 10 |
M echanism of NYX-2925 is highly relevant in advanced DPN patients with longer duration of chronic pain Results support and inform future Phase 2 study, initiation expected in 2019 EVANSTON, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage bio...
EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will pr...
Evogene (NASDAQ: EVGN ) +34% . on develop medical cannabis products. More news on: Evogene Ltd., InspireMD, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...
Aptinyx (NASDAQ: APTX ) is up 13% premarket on robust volume in reaction to preclinical data on its NMDA receptor modulator NYX-458. The results were presented at the International Conference on Alzheimer's & Parkinson's Diseases in Lisbon, Portugal. More news on: Aptinyx...
EVANSTON, Ill., April 03, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modula...
Noteworthy events during the week of March 31 - April 6 for healthcare investors. More news on: Evoke Pharma, Inc., ADMA Biologics, Inc., PolarityTE, Inc., Healthcare stocks news, , Read more ...
EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detai...
EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its...
Aptinyx Inc. (APTX) Q4 2018 Results Conference Call March 21, 2019 08:00 AM ET Company Participants Nick Smith - Senior Director, Corporate Development Norbert Riedel - President and CEO Ashish Khanna - CFO and Chief Business Officer Andy Kidd - COO Conference Call Participa...
Aptinyx ( APTX ) Q4 results : Revenues: $1M (-16.7%). More news on: Aptinyx Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...